Virus-like particle(VLP) platform technology is an emerging technology maximizing values of bio-pharmaceuticals including vaccines and anticancer drugs. POSVAX Co., LTD was established in 2018, we are “Bio-pharmaceutical company based on VLP platform technology”. The researchers have strived to develop bio-pharmaceuticals utilizing VLP platform technology since 2004. We are now concentrating on developing premium vaccines and anticancer drugs using VLP-based technology.

The researchers in POSVAX have established the technology to select the perfect form of virus-like particles based on protein structure analysis and immunological researches for the last 15 years. We already have secured a higher level of manufacturing technology for highly pure VLPs through applying genetic recombination technology and enhanced culture-purification technology. With these technologies, based on VLP platform, we aim to develop near-impossible and highly valuable prophylactic vaccines for cervical cancer, head-neck cancer, RSV, and Alzheimer's disease. Furthermore, using the accumulated technology, we will also develop new anticancer drugs with high efficacy.

We, POSVAX, will always try our best to contribute to the promotion of health and well-being of mankind by meeting unmet needs using our VLP technology.